Kymera Therapeutics, Inc. (KYMR) stock
Close on Nov 12, 2026Market cap $10.86BP/E –Yield –
Kymera Therapeutics, Inc. grew revenue 133.8% to $102.24M over the twelve months to Sep 30, 2026. Free cash flow was -$288.89M. At the latest close the market valued the company at $10.86B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.86B
- P/E ratio
- –
- Price to sales
- 106.19
- Price to book
- 6.72
- Dividend yield
- –
- Free cash flow yield
- -2.66%
Fundamentals
- Revenue
- $102.24M
- Net income
- -$349.43M
- EPS, diluted
- -$3.62
- Free cash flow
- -$288.89M
- Book value per share
- $16.13
- Diluted shares
- 100M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $134.84
- Open
- $134.19
- Day's range
- $126.94 – $134.67
- Volume
- 685,032
- Average volume (20 days)
- 975,533
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 1.90
- 52-week range
- $61.50 – $142.92
- RSI (14 days)
- 54.5
- Volatility (1 year)
- 63.0%
- Relative volume
- 0.88×
- WACC
- 14.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KYMR | S&P 500 | Difference | KYMR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.5% | -2.7% | +16.2 pts | ||
| 3 months | +11.5% | -1.7% | +13.3 pts | ||
| Year to date | +63.4% | +11.9% | +51.5 pts | ||
| 1 year | +100.2% | +12.0% | +88.2 pts | ||
| 3 years | +775.8% | +78.2% | +697.6 pts | +106.1% | +21.2% |
| 5 years | +102.2% | +73.2% | +29.0 pts | +15.1% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kymera Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Kymera Therapeutics
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule therapeutics using targeted protein degradation. The company's technology engages cellular recycling machinery to selectively eliminate disease-causing proteins, particularly historically undrugged transcription factors and scaffolding proteins. Its pipeline centers on immunology programs, including KT-621 targeting STAT6 for inflammatory conditions such as atopic dermatitis and asthma, and KT-579 targeting IRF5 for autoimmune disorders. Kymera also advances partnered programs, including an IRAK4 degrader with Sanofi and cyclin-dependent kinase 2 molecular glue degraders with Gilead Sciences, alongside early-stage oncology research. The company targets patients suffering from immune-inflammatory diseases and cancers.
Company profile, executives and historyKymera Therapeutics stock: common questions
What is Kymera Therapeutics's stock price?
KYMR closed at $127.17 on Nov 12, 2026, down 5.69% on the day. Over the past 52 weeks it traded between $61.50 and $142.92.
What is Kymera Therapeutics's market cap?
Kymera Therapeutics was worth $10.86B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KYMR's P/E ratio?
Kymera Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.62), so it has no meaningful P/E ratio.
How much revenue does Kymera Therapeutics make?
Kymera Therapeutics reported revenue of $102.24M for the twelve months to Sep 30, 2026, up 133.8% from a year earlier.
Does Kymera Therapeutics pay a dividend?
No. Kymera Therapeutics has not paid a cash dividend over the last twelve months.
When does Kymera Therapeutics report earnings next?
Kymera Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has KYMR stock performed over the past year?
Including dividends, KYMR returned +100.2% over the past year, against +12.0% for the S&P 500.
How many KYMR shares are sold short?
8M shares were sold short at the latest FINRA report, 15.96% of the float, or 10.5 days of average trading volume.
Who are Kymera Therapeutics's competitors?
Companies most similar to Kymera Therapeutics by business, industry and size include GLUE, CCCC, IPSC, BDTX, MAZE.
See a number that looks wrong?